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Abstract: Acute kidney injury (AKI) is an important health problem, affecting 13.3 million individ-
uals/year. It is associated with increased mortality, mainly in low- and middle-income countries,
where renal replacement therapy is limited. Moreover, survivors show adverse long-term outcomes,
including increased risk of developing recurrent AKI bouts, cardiovascular events, and chronic
kidney disease. However, there are no specific treatments to decrease the adverse consequences of
AKI. Epidemiological and preclinical studies show the pathological role of inflammation in AKI,
not only at the acute phase but also in the progression to chronic kidney disease. Toll-like receptors
(TLRs) are key regulators of the inflammatory response and have been associated to many cellular
processes activated during AKI. For that reason, a number of anti-inflammatory agents targeting
TLRs have been analyzed in preclinical studies to decrease renal damage during AKI. In this review,
we updated recent knowledge about the role of TLRs, mainly TLR4, in the initiation and development
of AKI as well as novel compounds targeting these molecules to diminish kidney injury associated to
this pathological condition.
Keywords: toll-like receptors; inflammation; acute kidney injury; drugs; therapy
1. Introduction
Acute kidney injury (AKI) is characterized by an acute loss of renal function. In clin-
ical practice, AKI is defined by an elevation of creatinine plasma concentration above
≥0.3 mg/dL in the first 48 h, an urine volume below 0.5 mL/kg/h for 6 h, or an 1.5 fold
increase in serum creatinine as compared with the baseline values [1]. Reduction in urinary
volume and urinary solute excretion leads to accumulation of waste products in the body
as well as dysregulation of blood pH and osmolarity, that may result lethal for the patient.
Depending on the intensity of AKI, the use of dialysis for patient survival may be necessary.
In the last years, the incidence of AKI has increased considerably as a consequence
of the high prevalence of AKI- associated comorbidities, such as aging, chronic kidney
disease (CKD), diabetes and hypertension, among others [2]. In fact, it has been estimated
that around 13.3 million people/year develop AKI [3].
Many people fully recover renal function after the AKI episode, however there are pa-
tients that progress to CKD, suggesting adverse chronic outcomes [4]. Indeed, AKI patients
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have a higher risk to develop CKD than healthy individuals. Moreover, AKI is associated
with high frequency of cardiovascular events and both early and long-term mortality [5].
Despite these adverse outcomes, there are no specific treatments to reduce chronic renal
damage after AKI. Therefore, it is necessary a better comprehension of the physiopathology
associated to this syndrome to identify novel therapeutic approaches. Toll like receptors
(TLRs) are immunity sensors that recognize a wide variety of endogenous and exogenous
molecules present in AKI and promote activation of intracellular pathways associated to
renal damage [6]. In this review, we updated recent knowledge about the role of TLRs as
potential drug targets to prevent and/or retard AKI-associated complications.
2. Pathophysiology of AKI
The etiology and pathophysiology of AKI are complex and multifactorial. AKI can
be classified into three different types: pre-renal, intrinsic and post-renal. Pre-renal AKI is
associated to a decreased renal blood flow by hypovolemia, impaired cardiac function, sys-
temic vasodilation or increased vascular resistance, thus leading to a reduced glomerular
filtration rate (GFR). Intrinsic AKI is related to direct injury or nephrotoxicity of parenchy-
mal renal cells (glomeruli, tubules, interstitium and endothelial cells). Post-renal AKI is
mainly related to a reduction in GFR as consequence of increased intra-tubular pressure by
obstruction of urinary tract [7].
The underlying pathophysiological mechanisms in AKI include hemodynamic changes,
direct tubular toxicity (mainly in proximal tubular cells), obstruction and dysfunction of mi-
crovascular vessels, congestion of tubular lumen, and renal inflammation [8]. These pathogenic
mechanisms may co-exist in AKI-patients, thus complicating diagnosis and treatment.
AKI depends on the duration and severity of the insult [9]. When acute renal damage
occurs, there is a first phase of tubular death, followed by a phase of cell regeneration and
recovery of the renal function. Massive tubular cell death results from different causes,
such as toxic insults, sepsis, oxidative stress, or ischemia, among others [10]. If the cause of
kidney damage is prolonged over time, it can trigger more severe tubular cell death. During
this process, tubular cells release chemokines, cytokines and other inflammatory stimuli
that promote leucocyte infiltration in the kidney [11,12]. Inflammation is important for the
regeneration and replacement of necrotic cells during AKI [13,14]. However, exacerbated
or unresolved inflammation triggers the activation of fibrosis, a phenomenon that may be
involved in progression to CKD after AKI [8].
3. Biomarkers in AKI
In the current clinical practice, AKI diagnosis is mostly based in determination of
serum creatinine concentration [15]. However, the levels of this nitrogen-containing com-
pound only increase when kidney injury is well stablished, restricting the possibility to
detect early phases of AKI [16]. In addition, many factors influence serum creatinine
concentration e.g., age, gender, diet, muscle mass, and hydration status), limiting its utility
as an AKI biomarker. For these reasons, there is a great interest in the search of new AKI
biomarkers for early detection, differential diagnosis and prognosis [17,18]. In this context,
the most promising AKI biomarkers are listed in Table 1. These novel biomarkers are
related with pathological processes involved in AKI development, such as inflammation,
oxidative stress and renal cells death [19,20]. Furthermore, current studies support the
potential value of circulating and urinary miRNAs as novel AKI biomarkers e.g., miR-21,
miR-30a-e and miR-494, among others [18,21,22].
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Table 1. AKI biomarkers.
Biomarker Function Origin Samples
Cystatin C Extracellular cysteine protease inhibitor All nuclear cells Serum
NGAL Limits bacterial growth by sequestering iron-containingsiderophores Neutrophils Serum/Urine




TIMP2 Peptidase involved in MMP inhibition and ECM degradation
CCL14 Pro-inflammatory chemokine
IL-18 Pro-inflammatory cytokine
KIM-1 Phosphatidylserine receptor that recognizes apoptotic cells andoxidized lipoproteins
Tubular cells
NAG Hydrolytic lysosomal enzyme
NHE3 Sodium–hydrogen exchanger in apical side of the epithelial cells
α/π-GST Phase II enzyme involved in cellular detoxification
ALAP
Enzymes involved in tubular damageAP
γGT
L-FABP Cytoplasmic proteins involved in binding, transport andmetabolism of LCFAs
Abbreviations: CCL14: Chemokine (C-C motif) ligand 14; ECM: Extracellular matrix; GST: Glutathione-S-transferase; IGF: Insulin growth
factor; IGFBP7: Insulin-like growth factor-binding protein 7; IL-18: Interleukin-18; KIM-1: Kidney injury molecule-1; LCFA: Long-chain
fatty acid; L-FABP: liver-type fatty acid binding protein; NAG: N-acetyl-β-D-glucosaminidase; NHE3: Sodium-hydrogen exchanger
isoform 3; NGAL: Neutrophil gelatinase-associated lipocalin; MMP: Metalloproteinase; TIMP2: Tissue inhibitor of metalloproteinases-2.
4. Toll-Like Receptors: Structure, Localization and Function
TLRs are composed by 10 members in humans (TLRs 1–10) and 12 in mice (TLRs 1–9,
and TLRs 11–13) [23]. TLRs are type I transmembrane glycoproteins with a structure com-
posed of three regions: (1) a N-amino terminal extracellular domain containing leucine-rich
motifs with a horseshoe-like structure responsible for ligand recognition, (2) a transmem-
brane domain and (3) a conserved cytoplasmic TIR (toll-interleukin 1 receptor) domain,
required for the activation of downstream signal pathways [24].
TLRs recognize PAMPs (pathogen-associated molecular patterns), which are structural
motifs found in viruses, fungi, and bacteria [25]. Cell membrane TLRs (TLR4, TLR5 and
TLR10 as well as heterodimers of TLR2 with TLR1 and TLR6) are recruited to phagosomes
after activation by their respective ligands e.g., LPS, lipoproteins, flagellin) [26]. By contrast,
TLRs involved in the recognition of nucleic acid-like structures e.g., dsRNA, ssRNA,
unmethylated CpG motifs) are localized in the endoplasmic reticulum, endosomes and
lysosomes (TLR3, TLR7 and TLR9) [27]. Furthermore, TLRs can also recognize endogenous
stress signal or DAMPs (damage-associated molecular patterns), including heat shock
proteins (Hsp), extracellular matrix components (fibrinogen, hyaluronic acid), nuclear
cytosolic proteins (HMGB1, high mobility group box protein 1) and elements from damaged
cells or organelles [28]. TLRs are activated by interaction with their ligands, leading to
the production of inflammatory cytokines, chemokines and interferons (IFNs). Moreover,
TLRs participate in maturation and differentiation of antigen-presenting cells, thus linking
innate and adaptive immune response [29]. TLRs gene expression has been reported on
immune (e.g., spleen, thymus, lymph nodes) [25] and non-immune tissues (skeletal muscle,
brain, heart, liver, kidneys, lung, intestine and pancreas, among others) [29], as well as all
innate [30] and adaptive immune cells [31].
TLR4 is the best characterized TLR in AKI. Therefore, in this review we will focus
on this molecule in relation to AKI progression and associated complications. TLR4 is
necessary for recognizing and facilitating responses to LPS in mammals [23]. In addition
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to LPS, numerous TLR4 ligands have been identified, including both PAMPs (various
viral fusion and envelope proteins) and DAMPs (HMGB1, Hsp60 and Hsp70, fibrinogen,
fibronectin, hyaluronic acid and heme, among others) [29,32,33]. With an almost identical
expression profile in humans and mice, TLR4 is mainly found in peripheral blood lympho-
cytes and spleen. As compared with spleen, moderate levels of TLR4 expression have been
reported in lungs, intestine, ovary, and placenta, while the lowest TLR4 expression has
been observed in heart, brain, liver, kidneys, muscle, pancreas, testis and thymus [34].
Under physiological conditions, TLR4 is widely expressed in renal parenchymal cells
and resident immune cells. TLR4 expression is elevated in renal cortex, whereas low
levels have been described in renal medulla. In the cortex, TLR4 expression is mainly
detected in proximal and distal tubules, but also in podocytes, glomerular mesangial cells,
peritubular endothelial cells and collecting duct cells [35]. In normal conditions, renal TLR4
expression is low, however the expression of this molecule increases in response to renal
injury and/or infection. For example, after ischemia/reperfusion injury, increased level of
TLR4 expression has been detected in renal endothelial cells [36], tubules and infiltrating
leukocytes [37,38]. In sepsis-induced AKI, elevation of renal TLR4 was reported in proximal
and distal tubules and in peritubular and glomerular capillaries [39]. TLR4 expression is
also upregulated in the kidney in cisplatin-mediated AKI [40], cyclosporin nephrotoxic-
ity [41], lupus nephritis [42], unilateral ureter obstruction [43], diabetic nephropathy [44]
and rhabdomyolysis-induced AKI [45]. These observations suggest that TLR4 plays an
important role in pathophysiology of AKI and may be a potential therapeutic target to
diminish renal damage in response to these pathological stimuli.
5. TLR4 Signaling Pathways
Recognition and binding of TLR4 with its respective ligands seems to require the
presence of cell surface adaptors. For example, LPS binds to LBP (LPS-binding protein)
and this complex is further recognized by the membrane protein CD14 [46]. CD14 transfers
LPS to MD-2, a beta-cup folded protein necessary for LPS-mediated TLR4 dimerization.
Therefore, TLR4 recognition and activation by LPS requires coordination of a complex
consisting of LBP, CD14 and MD-2, which act sequentially to promote TLR4 signaling [47].
Diverse ligands activate TLR4 through the binding with one or more members of the
LPS-multi-receptor complex [48]. However, further research is needed to identify which
proteins are involved in TLR4-mediated recognition of each specific ligand.
In addition to LPS, TLR4 recognizes several exogenous and endogenous ligands.
Upon ligand binding, TLR4 homodimerizes and initiates intracellular signaling through
two major downstream pathways: (1) from the plasma membrane, the MyD88-dependent
pathway, which activates early NFκB activation and cytokines production, and (2) from the
endosome, the MyD88-independent TRIF-dependent pathway, which upregulates type I
IFNs and a late phase NFκB activation [24,49] (Figure 1). Early phase of TLR4 activation is
triggered from the cell surface after ligand recognition. TLR4-mediated MyD88-dependent
signaling pathway requires the initial interaction with the sorting adaptor TIRAP (TIR
domain-containing adapter protein), present in regions enriched with phosphatidylinositol
4,5-bisphosphate, such as lipid rafts [48,50]. TIRAP contains a TIR domain that enables the
interaction of MyD88 with the TIR domain of TLR4, leading to the creation of a complex:
the myddosome [51,52]. Thus, myddosome is composed by MyD88, TIRAP, and IRAK
(interleukin-1-receptor-associated kinase). The binding of MyD88 to IRAK4 induces phos-
phorylation of IRAK1, which induces its kinase activity [53,54]. Then, activated IRAK1 au-
tophosphorylates and this hyperphosphorylation enables TRAF6 (TNF-receptor-associated
factor 6) to bind to this complex. IRAK-TRAF6 then interacts with a complex formed by
TAK1 (TGF-β Activated Kinase 1), TAB1 (TGF-β Activated Kinase 1 Binding Protein 1),
TAB2 and TAB3 [24]. In a further step, TAK1 is activated by TRAF6 [55]. Once activated,
TAK1 phosphorylates the IKK complex [56]. Next, the IKK complex phosphorylates the
NFκB inhibitory protein IκBα, allowing the nuclear translocation of NFκB and the sub-
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sequent expression of proinflammatory genes [57]. Besides activating NFκB, TAK1 also
phosphorylates MAPKs (p38, JNK and ERK), amplifying the inflammatory response.Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 5 of 27 
 
 
Figure 1. TLR4 signaling pathway. Upon ligand recognition, TLR4 forms homodimers and signals 
through MyD88-dependent and MyD88-independent pathways. In early phase of TLR4 activation, 
MyD88-dependent pathways begins with TIRAP and MyD88 recruitment to TLR4 and subse-
quently assembly with TRAF6, IRAK1 and IRAK4. TRAF6 associates with the complex formed by 
TAB1, TAB2, TAB3 and TAK1. Once activated, TAK1 mediates the phosphorylation of the IKK 
complex (IKKα, IKKβ, and IKKγ), which phosphorylates the inhibitory subunit IkB, resulting in 
nuclear NFκB translocation and proinflammatory genes expression. Besides activating NFκB, 
TAK1 also phosphorylates and activates MAP kinases (ERK, Jnk, p38) to further reinforce the pro-
inflammatory cytokines expression. MyD88-independent pathway requires the recruitment of 
TRIF and TRAM to TLR4 after its internalization in endosomes. The subsequent association with 
RIP1 and TRAF6 converges in the activation pathway of NFκB in a late phase of TLR4 activation. 
TRAF3 activates IRF3 through IKKε and TBK1, inducing transcription of type I interferons and 
IFN-inducible genes. Created with BioRender.com. 
After early TLR4 activation, the receptor is redirected towards the endosome and 
promotes a late phase of NFκB activation and IFN production [58]. Innate immune cells 
efficiently use endocytosis to degrade microorganisms in the lysosomal compartment. 
Additionally, pathogens routinely use the endocytic pathway to gain access to the cytosol. 
Therefore, endosomes are a perfect place to find immune receptors, such as TLR4. CD14 
plays a key role in LPS-mediated TLR4 endocytosis [59]. In this case, the TIRAP-MyD88 
complex is released from the invaginated cell membrane, allowing TRIF (TIR-domain-
containing adaptor protein inducing IFNβ) and TRAM (TRIF-related adaptor molecule) 
to engage the TIR domain of TLR4. Then, TRAF3 recruited by TRIF interacts with IKK-
related kinases for IRF3 phosphorylation and further dimerization [60]. AIRF3 dimers 
translocate into the nucleus to induce the expression of type I IFN genes [61]. TRIF also 
participates in recruitment of TRAF6 and the kinase RIP-1, which activates the TAK1 com-
plex. This leads to late activation of NFκB and MAPKs, with the subsequent inflammatory 
Figure 1. TLR4 signaling pathway. Upon ligand recognition, TLR4 forms homodimers and signals
through MyD88-dependent and MyD88-independent pathways. In early phase of TLR4 activation,
MyD88-dependent pathways begins with TIRAP and MyD88 recruitment to TLR4 and subsequently
assembly with TRAF6, IR 1 and IRAK4. TRAF6 associates with the complex formed by TAB1,
TAB2, TAB3 and TAK1. Once activated, TAK1 medi p osphorylation of the IKK complex
(IKKα, IKKβ, and IKKγ), which phosphorylates the inhibitory subunit IkB, resulting in nuclear
NFκB translocation and proinflammatory genes expression. Besides activating NFκB, TAK1 also
phosphorylates and activates MAP kinases (ERK, Jnk, p38) to further reinforce the proinflammatory
cytokines expression. MyD88-independent pathway requires the recruitment of TRIF and TRAM
to TLR4 after its internalization in endosomes. The subsequent association with RIP1 and TRAF6
converges in the activation pathway of NFκB in a late phase of TLR4 activation. TRAF3 activates
IRF3 through IKKε and TBK1, inducing transcription of type I interferons and IFN-inducible genes.
Created with BioRender.com.
After early TLR4 activation, the receptor is redirected towards the endosome and
promotes a late phase of NFκB activation and IFN production [58]. Innate immune cells
efficiently use endocytosis to degrade microorganisms in the lysosomal compartment.
Additionally, pathogens routinely use the endocytic pathway to gain access to the cytosol.
Therefore, endosomes are a perfect place to find immune receptors, such as TLR4. CD14
plays a key role in LPS-mediated TLR4 endocytosis [59]. In this case, the TIRAP-MyD88
complex is released from the invaginated cell membrane, allowing TRIF (TIR-domain-
containing adaptor protein inducing IFNβ) and TRAM (TRIF-related adaptor molecule) to
engage the TIR domain of TLR4. Then, TRAF3 recruited by TRIF interacts with IKK-related
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kinases for IRF3 phosphorylation and further dimerization [60]. AIRF3 dimers translocate
into the nucleus to induce the expression of type I IFN genes [61]. TRIF also participates in
recruitment of TRAF6 and the kinase RIP-1, which activates the TAK1 complex. This leads
to late activation of NFκB and MAPKs, with the subsequent inflammatory cytokines gene
expression [48]. Remarkably, NFκB activation shows a delayed peak in Myd88-deficient
cells compared with wild-type cells, supporting a late, Myd88-independent pathway of
NFκB activation [62].
6. TLR4 Mediated Effects
TLR4 is a key molecule involved in the pathogenesis of inflammatory diseases [63,64].
Indeed, reports on PAMPs recognition mediated by TLR4 strongly support its role against
different pathogens, mediating both secretion of proinflammatory cytokines and chemotac-
tic factors that mediate the local recruitment of immune cells, including neutrophils and
macrophages [46,65–67]. Additionally, TLR4 recognition of DAMPs in damaged tissues
further contributes to local inflammation and fibrosis [68]. The damaged epithelial and
endothelial cells produce cytokines and chemokines that contribute to attract immune cells
to the wounded tissue [69].
Upon infection, bone marrow (BM)-derived myeloid cells are produced and then
recruited to damaged tissues where they differentiate to dendritic cells and macrophages,
contributing to the initial local inflammatory response [70,71]. Additionally, BM-derived
monocytes with a patrolling profile are abundant during the late stages of local inflam-
matory processes and participate in its resolution and tissue repair, but also may produce
fibrosis [64,65,71]. Alterations in vascular permeability mediated by TLR4 interactions
allow infiltration of circulating cells in the injured tissues. Endothelial TLR4 is involved in
neutrophil recruitment during LPS-induced systemic sepsis [72]. Extracellular histones,
released from necrotic tubular epithelial cells during AKI, induce the secretion of the
proinflammatory cytokines by BM–derived dendritic cells through TLR2 and TLR4 recog-
nition [73]. Glucose induces TLR4 expression in podocytes and tubular cells and increases
inflammation, renal injury and fibrosis in diabetes nephropathy, effects that were not
observed in TLR4 deficient mice [74].
TLR activation alters the renal redox homeostasis [75–77]. In the kidney, accumulation
of ROS (reactive oxygen species) and RNS (reactive nitrogen species) induces renal dysfunc-
tion [78] as well as increased TLR4 and Hsp70 expression by tubular cells [79]. TLR4/NLRP3
and TLR4-NK-κB are the principal pathways able to modulate the mitochondria-related
oxidative damage. Different studies have demonstrated that TLR4 knockout mice are
protected from renal injury since they have lower levels of chemokines and less granu-
locytic recruitment [38]. In the case of MyD88 and TRIF deficient mice the results are
controversial [80].
In the first hours after AKI, TLR4 plays a fundamental role in the induction of adhe-
sion molecules by vascular endothelium [36], facilitating infiltration of leukocytes to renal
parenchyma [81]. TLR4 activation is also involved in endothelial dysfunction, causing
abnormal vascular tone, hyperpermeability and proteinuria [82,83]. All these cellular
dysfunctions may lead to important alterations in the microcirculation after TLR4 activa-
tion [84]. However, although inhibition of TLR4 improved renal function in a pre-clinical
study, this protective effect was independent of restoration of macro-circulation or micro-
circulation [85].
Renal damage induces an inflammatory response and apoptotic mechanism [86,87].
In the initial phase of tissue damage, renal tubular epithelial cells express markers of
early apoptosis (caspase-8 and Bax, among others) [88]. In sepsis conditions, TLR2−/−,
TLR4−/− and MyD88−/− deficient mice, present reduced renal apoptotic rates compared
to wild type mice, favoring clearance of damaged cells [80]. Furthermore, in MyD88−/−
mice, the anti-apoptotic bcl-2 protein is elevated compared to wild type mice, which results
in protection from death [82]. In vitro analyses confirmed the notion that TLR4/MyD88/NF-
κB axis regulates inflammatory response and apoptosis after renal injury [89]. In the context
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of renal damage, TLR4 can be activated by alarmins (endogenous ligands for TLR4; i.e.,
HGMB1 and Hsp70) as a consequence of cellular stress, amplifying kidney injury [90].
Both alarmins are elevated in septic mice (wild type, TLR2−/−, TLR4−/−), but not in
the case of MyD88−/− mice [82]. In human biopsies, enhanced HGMB-1 is detected after
renal graft ischemic transplantation [91]. Increased expression of KIM-1 (kidney injury
molecule-1) and mTOR (mammalian target of rapamycin) was found in sepsis-associated
AKI. These molecules are important downstream mediators of TLR4 activation in this
pathological scenario [82,92].
7. Regulation of the TLR4 Pathway
TLR4 is essential for triggering an inflammatory response after PAMPs and DAMPs
recognition. However, excessive, uncontrolled and/or sustained activation of these TLRs
may lead to a chronic inflammatory state that promotes the development of several immune-
mediated diseases. Therefore, strict negative regulation of TLR4 signaling is required to
protect the host from an exacerbated inflammatory response. Modulation of TLR4 activa-
tion and their downstream-related signaling pathways include several mechanisms, such as
soluble decoy receptors, transmembrane regulators, cellular trafficking, destabilization
of adaptor proteins, ubiquitination, dephosphorylation, transcriptional regulation and
feedback inhibition (Table 2).
Table 2. Mechanisms of negative regulation of TLR4 pathway.
Regulation Regulator Proposed Mechanism References




Bind to Myd88 and IRAK to reduce their recruitment to TLR4 [95,96]
SIGIRR
RP105 Associates with TLR4 extracellular domain and prevents ligand binding [97]
Cellular trafficking Rab7 Promotes TLR4 endosomal internalization and degradation [98]
Adaptor proteins
Myd88s Heterodimerizes with Myd88 and inhibits its interaction with IRAK4 [99]
TOLLIP Reduces IRAK1 autophosphorylation and promotes its degradation [100]
SOCS1 Induces TIRAP and p65 degradation [101]
Ubiquitination
A20 Promotes deubiquitination of TRAF6 [102]
TRIAD3A Induces TLR4 ubiquitination and subsequent degradation [103]
Phosphorylation
SHP1 Dephosphorylates IRAK1 [104]
SHP2 Dephosphorylates TBK1 [105]
Transcriptional
regulation
TGFb Inhibits TLR4 gene expression and promotes Myd88 degradation [106,107]
IL10 Reduces TLR4, Myd88, IRAK1 and TRAF6 expression [108]
miR-155-5p Reduces Myd88 expression [109]
miR-210-5p Inhibits NFkB1 mRNA subunit [109]
Feedback inhibition
TRIM30α Promotes TAB2 and TAB3 degradation [110]
IκBNS Reduces IL6 gene expression [111]
Bcl3 Blocks p50 ubiquitination and prevents DNA binding of NFkB [112]
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Several studies have reported the existence of soluble forms of receptors that act as
decoy for ligands and coreceptors of transmembrane receptors themselves, thus preventing
ligand-receptor interaction and their subsequent activation. This is the case of the soluble
form of TLR4 (sTLR4). It has been demonstrated that recombinant sTLR4 significantly
reduced NFκB activation and TNFα production in vitro [93] through its association with
TLR4 ligands and coreceptors like MD2 and CD14 [84]. The assembly with sTLR4 prevented
the interaction of ligands and coreceptors with transmembrane TLR4, therefore efficiently
attenuating TLR4 activation.
Negative modulation of TLR4 also involves transmembrane proteins with an intra-
cellular TIR domain, such as ST2L and SIGIRR. Through this TIR domain, ST2L and
SIGIRR can bind to MyD88 and IRAK and, as a result, hinder their recruitment after TLR4
activation [95,96]. Increased levels of ST2L has been reported in infection- and obstructive-
associated renal injury [113]. SIGIRR deficiency increased renal proinflammatory cytokine
levels and aggravated post-ischemic AKI [114]. However, lack of SIGIRR did not prevent
postobstructive renal fibrosis [43]. There are other transmembrane proteins without TIR
domain that also have an inhibitory effect on TLR4. For example, RP105 associates directly
with the TLR4 extracellular domain, avoiding ligand binding to this receptor, thereby
inhibiting TLR4 signaling [97].
TLR4 subcellular location also represents a target for negative regulation of the recep-
tor. From the cell surface, TLR4 activation induces a MyD88-dependent pathway, while its
endocytosis triggers a MyD88-independent pathway. Different proteins modulate TLR4
internalization and trafficking and promote signaling through one of these pathways [115].
After stimulation, Rab7 protein leads TLR4 to the lysosomal compartment for degradation,
preventing its activation and favouring its turnover [98]. A recent study has reported
elevated levels of Rab7 after ischemia-reperfusion kidney injury. However, the authors
have related this elevation to autophagy activation after renal injury, independently of the
acute inflammatory response triggered by TLRs [116].
Intracellular proteins recruited after TLR4 activation (Myd88, TRAF6, IRAK and TIRAP)
are involved in modulation of TLR4 signaling. Several adaptors variants act as negative
regulators, thus preventing downstream signaling. One of these adaptor variants is MyD88s,
an alternative form of MyD88 without the interdomain. MyD88s heterodimerizes with
MyD88, inhibiting MyD88-IRAK4 interaction and preventing subsequent IRAK4-mediated
IRAK1 phosphorylation, decreasing downstream signaling [99]. IRAK1 is also modu-
lated by TOLLIP, which reduces its autophosphorylation and favours its ubiquitination,
inhibiting post-IRAK1 signaling [100]. In a sepsis model of renal injury, TOLLIP inhib-
ited LPS-induced TLR4 signaling by suppressing IRAK1 activation [117]. TOLLIP gene
expression was reduced in experimental ischemia-reperfusion AKI [118]. Another key
modulator in TLR4 signaling is SOCS1 (Suppressor of Cytokine Signaling 1). SOCS1 is
induced upon receptor activation and modulates TLR4 through two mechanisms. First,
SOCS1 interacts directly with TIRAP and initiates its degradation through ubiquitina-
tion. Second, SOCS1 directly associates with p65 subunit of NFκB and induces its pro-
teasomal degradation, thereby suppressing the activation of NFκB [101]. Induction of
Jak2/STAT3/SOCS1 pathway had a protective effect in acute kidney graft rejection [119].
In a murine model of cisplatin-induced AKI, SOCS1 expression was decreased, whereas
induction of Jak2/STAT1 pathway with an AMPK activator restored SOCS1 levels and
promoted renal protection [120]. Additionally, SOCS1-targeted therapy limited progression
of diabetic nephropathy [121–123].
Ubiquitination and dephosphorylation of TLR4 or the proteins involved in TLR4
signaling is essential for the modulation of this signaling pathway. For example, the deu-
biquitinating enzyme A20 inhibits TLR4 mediated signaling by deubiquitination of TRAF6
and therefore blocks effectively MyD88 dependent and independent pathways [102]. In-
duction of A20 in renal proximal tubular epithelial cells showed an anti-inflammatory and
anti-apoptotic effect [124]. In ischemia-reperfusion renal injury, A20 has also a protective
role by suppressing pro-inflammatory pathways [125,126]. Moreover, TRIAD3A promotes
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ubiquitination and subsequent degradation of TLR4 receptor itself [103]. Overexpression of
TRIAD3A was reported in diabetic nephropathy [127]. Additionally, TLR4 signaling can be
limited by the tyrosine phosphatases SHP1 and SHP2. These enzymes catalyze the dephos-
phorylation and consequent inhibition of IRAK1 and TBK1, respectively. In a recent study,
SHP1 inhibited renal ischemia-reperfusion injury by dephosphorylating ASK1 and sup-
pressing apoptosis. Consistently, SHP1 knockdown mice showed significantly increased
renal injury and aggravated the apoptosis of tubular epithelium cells [128]. Controversially,
genetic deficiency or inhibition of SHP2 seems to have a beneficial effect in kidney damage.
PHPS1, an inhibitor of SHP2, attenuated renal injury in a murine model of hemorrhage
followed by sepsis [129]. SHP2 knockout in myeloid cells protected the kidneys from
inflammatory damage and prevented renal fibrosis after unilateral ureter obstruction [130].
SHP2 deficiency also had a protective effect in renal ischemia-reperfusion [131]. SHP2
is assumed to have an additional role as an antagonist of TBK1 beyond its phosphatase
activity [104,105]. Ligand binding leads to phosphorylation of tyrosine residues within
the TIR domain of TLR4. This phosphorylation is required for TLR4-induced activation of
NFκB. Although the mechanisms are not completely understood, tyrosine kinases like Src
and Btk modulate TLR4 phosphorylation state by binding to the receptor after its activation.
Inhibition of these kinases reduce TLR4 phosphorylation and signaling [115].
TLR4 signaling can also be modulated by reducing the expression of this receptor.
The expression of TLR4 can be downregulated by TGF-β and the anti-inflammatory cy-
tokine IL-10. Specifically, TGF-β inhibits TLR4 gene expression and promotes MyD88 degra-
dation, thus decreasing downstream signaling [106,107]. On the other hand, IL-10, through-
out miR-146b, reduces the expression of TLR4, MyD88, IRAK1 and TRAF6 [108]. Several
studies have identified other miRNAs involved in the modulation of these molecules.
For example, miR-155-5p reduces the expression of MyD88 and causes the abrogation
of NFκB activation. miR-155-5p is highly expressed in kidneys from renal patients and
experimental obstructive renal models, promoting renal fibrosis [132]. However, the re-
lationship between miR-155-5p and acute renal inflammation has not been reported and
further studies are required. TLR4 activation increases the expression of miR-210-5p, which
also regulates the activation of NFκB pathway throughout inhibition of NFκB1 mRNA
subunit [109].
Feedback inhibition of TLR4 contributes significantly to the overall control of the
downstream signaling. Different studies support the existence of various proteins that
are induced after TLR4 activation and that negatively modulate this signaling pathway.
TRIM30α, a member of TRIM protein superfamily, is induced after TLR4 ligand recog-
nition and activation. This protein enhances the degradation of TAB2 and TAB3 and
effectively inhibits NFκB activation [110]. TLR4 also increases the expression of other
negative modulators, including IκBNS and Bcl3. IκBNS binds to IL-6 promoter and reduces
its induction [111]. Bcl3 attenuates the inflammatory response by associating with the
DNA binding site of NFκB p50 subunit, limiting its action [112]. Bcl3 expression was re-
ported upregulated in experimental AKI [133]. In vitro Bcl3 overexpression decreased NFκB
transcriptional activity, inflammation and cell death, whereas its downregulation resulted
in chemokine upregulation, sensitization to cell death and increased NFκB transcriptional
activity [133]. The aforementioned molecules and mechanisms represent promising targets for
the design of new therapeutic strategies against exacerbated TLR4-inflammatory response.
8. TLRs and AKI
There are multiple causes of AKI. For that reason, in the next section we will fully
describe the role of TRLs, mainly TLR4, in each specific AKI subtype (Figure 2).
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TRIF, and MyD88/TRIF knockout mice were protected against I/R damage [143]. The in 
vivo experiments developed by Rusai et al. described non-synergistic beneficial effects in 
TLR2 and TLR4 double knockout mice submitted to I/R as compared to single gene dele-
tion [144]. Induction of I/R injury in TLR4 knockout mice also protected from microvas-
cular rarefaction but not from the development of fibrosis [145]. A more severe injury after 
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Figure 2. TLR4 in the pathophysiology of AKI. Activation of TLR4 signaling pathway has been
observed in different types of AKI. On the one hand, models that reduce renal blood flow generate
an increase of TLR4 expression in endothelial, tubular and leukocyte cells. Endothelial dysfunction is
a common mechanism in all types of AKI. This dysfunction leads to an increase in the expression of
cell-adhesion molecules, activation of the innate immune response (neutrophils and macrophages)
the concomitant maintenance of oxidative stress. On the other hand, the presence and/or
release of endo/exot xins in some AKI, allows the development of endothe ial dysfuncti n as ell
as activation of platelets and c mplement casc de, whi h obstruct glomerular blood flow, d creasing
glomerular filtration rate. Other pathological changes detected in different types of AKI are largely
observed in the tubulointerstitial space, mainly related to accumulation of toxins. The maintenance
of a partial and/or total obstruction in the urinary tract, either by an exogenous (e.g., prostatic
hyperplasia) or endogenous mechanism (e.g., detritus overload), produces an increase in luminal
pressure, dilation of the collecting ducts, loss of functional units and development of tubulointerstial
fibrosis. The pre-renal, intrarenal and post-renal manifestations are closely linked and the affection
of one compartment has a direct impact on the others, enhancing the severity of AKI. Created with
BioRender.com.
8.1. Ischemia-Reperfusion
Ischemia reperfusion (I/R) injury is caused by a period of vascular occlusion followed
by blood supply to tissue. Blockade of blood flow induces hypoxia and accumulation of
metabolic products in the tissue [134]. Ischemic injury may be classified as warm, in the
case of vascular anastomosis, stroke or myocardial infarction, or cold ischemic injury,
as reported in tissue transplantation. The kidney is extremely sensitive to warm ischemia,
but relatively resistant to prolonged periods of cold ischemia [135]. The key problem in the
ischemic process is the subsequent period of reperfusion, which causes severe renal injury
by activating the innate inflammatory response [136–138].
Several studies have described a deleterious role of TLRs in AKI induced by I/R.
The TLR3/TRIF/IRF-3 signaling pathway is activated in experimental I/R-associated
AKI [139]. In the same article, TLR3 knockout mice showed decreased renal injury, pre-
served renal perfusion, and reduced renal inflammation as compared with wild type mice,
suggesting that TLR3 is involved in renal IR injury [139]. Increased TLR2 and TLR4 gene
expression was reported in proximal and distal tubules after I/R damage [37].
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Some ligands of TLR2 and TLR4 such as hyaluronan, HMGB1 and brevican were also
elevated in this pathological setting [38]. Interestingly, the treatment with an antibody
against HMGB1 reduced recruitment of neutrophils and macrophages and diminished
inflammation and apoptosis in TLR4+/+ mice, but not in TLR4−/− mice, indicating the
key role of HMGB1/TLR4 axis in I/R injury [140]. A recent study identified miR-27a
as a negative regulator of TLR4 and demonstrated that overexpression of this miRNA
reduced TLR4 expression and consequently diminished I/R-mediated renal inflammation
and cell death [141]. On the other hand, the in vivo gene blockade of TLR2, TLR4 or
MyD88 demonstrated beneficial effects against renal I/R injury, including reduction of
inflammatory infiltrate, decreased epithelial cell death, reduced expression of cell adhe-
sion molecules, and amelioration of renal function [36,38,80,142]. In other study, TLR2,
MyD88, TRIF, and MyD88/TRIF knockout mice were protected against I/R damage [143].
The in vivo experiments developed by Rusai et al. described non-synergistic beneficial
effects in TLR2 and TLR4 double knockout mice submitted to I/R as compared to single
gene deletion [144]. Induction of I/R injury in TLR4 knockout mice also protected from mi-
crovascular rarefaction but not from the development of fibrosis [145]. A more severe injury
after I/R was observed in mice with targeted deletion of complement factor B and TLR2 as
compared to mice with single factor B deficiency [146]. Induction of hypoxia in cultured
proximal tubular epithelial cells demonstrated the stimulation of the endoplasmic-resident
gp96, a molecule that physically interacts with TLR4. This tandem is necessary for the
activation of ASK1/JNK signaling pathway. In addition to these data, NOX4 collaborated
with TLR4-mediated apoptosis in renal I/R [147]. Kidney transplantation is a pathological
situation closely related to I/R damage. In this setting, TLR2 or MyD88 gene deficiency
improved renal function and reduced chronic allograft damage by reducing cytokine and
chemokine expression (IL-6 and CCL2), leukocyte recruitment and fibrosis (collagen I and
III levels) in renal grafts [148]. A study of I/R AKI with mice deficient in TLR9 in tubular
cells reported an improvement in renal function, an effect not observed in total TLR9 knock-
out mice, suggesting the complex role of this protein in this pathology [149]. Treatment
with a TLR9 antagonist, reduced renal damage in mice [150]. Furthermore, activation of
TLR5 with its agonist CBLB502 reduced acute renal ischemic failure lesions [151].
Some compounds targeting TLRs expression have demonstrated beneficial effects
against I/R injury. The anti-inflammatory Maresin 1 reduced renal damage through
the modulation of TLR4 and ERK, JNK, and P38 signaling pathways in I/R mice [152].
Hesperidin also ameliorated renal function and reduced inflammatory mediators, oxidative
stress, as well as TLR4 and NFκB activation [153]. Eritoran is a molecule that inhibits
TLR4 dimerization [154] and attenuated the course of I/R injury by decreasing serum
creatinine, tubular damage markers (KIM-1, N-GAL), monocyte infiltration and expression
of IL-6, TNF-α and IL-1β [155]. Besides its effects targeting Nrf2, sulforaphane specifically
suppresses oligomerization of TLR4 and decrease inflammatory response [156]. In an acute
model of I/R, sulforaphane reduced renal injury, inflammation, oxidative stress and cell
death [157]. All together, these data demonstrate the essential role of TLRs in I/R injury as
well as kidney transplantation.
8.2. Toxin Induced AKI
8.2.1. Endogenous Toxicity (Pigment Nephropathy)
Excessive accumulation of endogenous toxins in the kidney may lead to AKI. This is
the case of rhabdomyolysis, a pathological condition characterized by massive muscle
injury and the consequent release of intracellular content into the bloodstream, mainly myo-
globin and heme-derivates. These molecules build up in the kidney, resulting nephrotoxic
and promoting AKI [158]. Heme directly activates TLR4, so TLR4 may play an important
role in rhabdomyolysis-induced AKI [159].
TLR4 has been proposed as a biomarker of rhabdomyolysis-AKI. Thus, TLR4 was
found in the urine as a consequence of protein cleavage and massive proximal tubular
cell death [160]. By contrast, low TLR4 levels were found in kidneys, probably due to
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tubular necrosis [160]. Pharmacological inhibition of TLR4 with TAK-242 suppressed
myoglobin-induced inflammatory response in cultured macrophages and tubular epithe-
lial cells [161,162]. TAK-242 inhibits TLR4 interaction with its adaptor molecules [163].
This small-molecule inhibitor decreased inflammatory cytokines production, macrophage
infiltration and renal damage in a rhabdomyolysis model induced by intramuscular in-
jection of glycerol [161]. In other study, rhabdomyolysis was induced by exerting 3 kg of
pressure for 8 h in rats, and treatment with TAK-242 reduced renal injury and decreased
systemic inflammatory cytokines (IL-6 or TNF-α) [164]. In line with this data, other studies
also reported that direct inhibition of the TLR-4/JNK/p38/NFκB pathway with curcumin
and loganetin [165,166], reduced kidney injury and inflammation, as well as improved
renal function in pre-clinical models of rhabdomyolysis [45,165]. However, there are con-
tradictory results in the literature, since TLR4 antagonism with TAK-242 did not protect
from rhabdomyolysis-mediated renal damage in other study [162]. Therefore, new studies
are necessary to address the contribution of TLR4 in rhabdomyolysis.
8.2.2. Exogenous Toxicity
The development of AKI can be a side effect of some pharmacological therapies. Cis-
platin, a drug used for the treatment of certain tumors and may induce AKI [167]. TLR4 has
been associated with cisplatin-induced AKI. Indeed, TLR4-knockout mice were protected
from kidney damage and showed lower levels of inflammatory cytokines and chemokines
than wild type mice after cisplatin administration [40,168,169]. In this line, the TLR4 in-
hibitor sulforaphane attenuated cisplatin-induced renal dysfunction, histological damage
and oxidative stress [170].
Certain antibiotics, such as aminoglycosides, also lead to AKI. There are fewer data
about the involvement of TLR4 in this type of AKI. However, two recent studies described
that pretreatment with pirfenidone or umbelliferone caused a reduction in renal damage
through the inhibition of the TLR4/NFκB/NLRP-3 pathway in an experimental model of
gentamicin-induced AKI [171,172].
Another nephrotoxic drug is acetaminophen [173]. TLR4 has been suggested as a
possible target against the organ failure caused by acetaminophen. Thus, TLR4 inhibition
with TAK-242 decreased kidney injury and improved renal function, but this study does
not clarify whether this protective effect is directly on the kidney or indirectly through the
hepato-renal crosstalk [174]. The involvement of TLR4 in the hepato-renal syndrome has
also been observed in experimental models, where increased renal TLR4 expression has
been described, mainly in tubular cells, and related to kidney injury [175]. This fact has
also been observed in cirrhotic patients that developed AKI [176].
Radiocontrast medium used in medical tests can lead to AKI [177]. Increased renal
TLR4 expression was observed after injection of contrast medium [178]. In this contrast
medium-induced AKI model, TAK-242 protected against tubular apoptosis and ROS
production by modulating NLRP3 inflammasome. These results were reproduced in
cultured rat kidney cells (NRK-52e), where TAK-242 decreased iopromide-mediated cell
death, oxidative stress and inflammation [178].
8.3. Sepsis-Induced AKI
Sepsis is a life-threatening pathological condition associated to a systemic infection
and that may lead to AKI (Sepsis-induced AKI (SI-AKI)) [179]. Despite a considerable
number of studies in recent years, the pathophysiology of SI-AKI is not fully understood,
and current treatment is limited to replacement of renal function by dialysis. In the past,
SI-AKI was related to hypoperfusion and the subsequent renal ischemia. However, re-
cent studies suggest that SI-AKI can also occur within normal blood pressure range and
maintained renal perfusion [84]. According to recent experimental and clinical studies,
pathophysiology of septic AKI is explained through three main mechanisms: alterations
in renal microcirculation related to endothelial dysfunction, inflammation, and adaptive
bioenergetic and metabolic downregulation in renal tubules [84]. This recent paradigm
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shift highlights the role of the inflammatory response in SI-AKI and points strongly to-
wards TLR4 as a potential mediator in the development of SI-AKI. LPS is the main ligand
for TLR4 [180]. The interaction between LPS and both systemic and renal TLR4 has been
reported in SI-AKI [181]. After polymicrobial sepsis, expression of TLR4 increases in renal
tubules, glomeruli and vasculature [39] and circulating endotoxins have been detected in
these locations [182]. Recent animal studies have demonstrated that targeting TLR4 with
specific antibodies reduce endotoxemia-associated mortality [183,184]. To further reinforce
the potential role of TLR4 in SI-AKI, C3H/HeJ mice characterized by a dysfunctional TLR4
showed an attenuated renal injury when subjected to LPS [87]. In humans, TLR4 polymor-
phisms have been related with a reduced LPS-mediated inflammatory response [185].
Based on the aforementioned data, different studies have been performed in order
to investigate whether TLR4 inhibition may have a renoprotective effect in SI-AKI. In a
sheep model of SI-AKI induced by intravenous LPS infusion, the selective TLR4 inhibitor
TAK-242 reduced plasma creatinine and BUN concentration [186]. TAK-242 also reduced
sepsis-mediated glomerular neutrophil infiltration and endothelial swelling, improved
creatinine clearance, glomerular filtration rate and urine output [85]. In a cecal ligation
and puncture model of SI-AKI, TLR4 knockout mice showed preserved renal morphology
and function, decreased vascular permeability and lower neutrophil infiltration in the
kidneys, as well as reduced IL-1β, TNF-α, IL-6 and IL-17 levels in the kidney and in the
peritoneal cavity, with a marked decrease in NFκB activation [82]. TAK-242 attenuated LPS-
mediated renal dysfunction and pathological damage by inhibiting TLR-4/MyD88/NFκB
signaling pathway [187]. TAK-242 also ameliorated LPS-mediated pro-inflammatory cy-
tokine expression and reduced NFκB activation in cultured renal epithelial cells [188,189].
Moreover, urinary inflammatory markers NGAL and IL-18 were also reduced by TAK-242
administration in I/R injury [190]. Resveratrol, a natural phytoalexin, also reduced TLR4
expression and NFκB activation in macrophages and mice with LPS-induced AKI [191].
In SI-AKI, hydrogen sulfide also reduced oxidative stress and pro-inflammatory cytokines
expression via the TLR4/NLRP3 signaling pathway [78,192]. Moreover, TLR4-mediated
expression of cell adhesion molecules (ICAM-1 and E-selectin) may contribute to renal
leucocyte infiltration and renal injury in SI-AKI [193,194].
Different studies have tried to determine the relative importance of renal and sys-
temic TLR4 in the recruitment of immune cells and renal injury in SI-AKI. In an animal
model of SI-AKI by LPS injection, wild type mice received transplanted kidneys from the
C3H/HeJ LPS-hyporesponsive mouse strain and developed renal inflammation and AKI
after LPS exposure, while C3H/HeJ with kidneys from wild type mice did not show these
alterations [87]. Therefore, this study emphasizes the essential role of systemic TLR4 for
the development of SI-AKI. In contrast, a more recent study supports the importance of
renal TLR4 in SI-AKI. The endotoxin increased tubular injury in mice without TLR4 in
hematopoietic cells but were TLR4 +/+ in renal cells. Conversely, mice with TLR4+/+
immune cells and TLR4−/− in renal cells had no tubular injury [195]. In addition to
these studies, results derived from a mouse model of pyelonephritis also using chimeric
mice suggest that both systemic and renal TLR4 are necessary for abscess formation and
leukocyturia in this model [196]. Even though it remains unclear whether the renal or
systemic TLR4 has a more important role, all these studies share the common protective
effect of the lack of TLR4 in the development of SI-AKI.
Beyond inflammation, SI-AKI is characterized by two additional pathological mecha-
nisms: dysregulated renal microcirculation and metabolic adaptation of renal cells to injury.
Although the connection with TLR4 might not be direct, as in the case of the inflammatory
response, recent evidence suggests the potential beneficial effect of TLR4 inhibition against
these harmful processes. Endothelial dysfunction in sepsis is characterized by dysregulated
renal blood flow and reduced GFR [197]. Pharmacological inhibition or genetic deletion of
TLR4 in pre-clinical sepsis models was associated with reduced glomerular endothelial
swelling and vascular permeability, respectively [82,85]. In a recent work LPS-mediated
reduction in GFR was abolished in TLR4 knockout mice, suggesting a TLR4-dependent
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mechanism [198]. Tubular cells exposed to inflammatory stimuli prioritize cell survival
over organ function [199]. Downregulation of renal sodium and chloride transporters
after LPS exposure has been previously described [197]. However, recent reports have
demonstrated that TLR4 signaling pathway is also involved in LPS-mediated inhibition of
HCO3(−) absorption in the kidney [92]. According to all these data, it is not possible to
deny the potential therapeutic effect of TLR4 inhibition against the complex pathological
consequences of SI-AKI (Table 3). However, it is important to keep in mind that TLR4 acti-
vation and its consequent pro-inflammatory response is necessary for bacterial elimination
during sepsis.
Other members of the TLRs family have been involved in SI-AKI. For example, TLR2
was overexpressed in glomerular endothelial cells and podocytes in a murine model
of SI-AKI [200]. TLR2 knockout mice subjected to cecal ligation and puncture (CLP)
had preserved renal morphology, less renal hypoxia, fewer areas of apoptosis, reduced
expression of proinflammatory cytokines and decreased vascular permeability compared
with wild type animals [82]. Another study has reported that histones released from dying
renal cells in AKI directly interact with TLR2 and TLR4. Extracellular histones induced
leukocyte recruitment, microvascular leakage and renal inflammation in a TLR2/TLR4
dependent manner [73]. Flagellin, the monomeric subunit of bacterial flagella, triggers
innate immune response through TLR5. A recent work compared the systemic effect of
LPS and flagellin administration in mice. Flagellin induced significant oxidative stress and
liver but not renal injury, whereas LPS caused less severe oxidative stress and triggered
renal but no hepatic damage [201]. Based on this work, the contribution of TLR5 to SI-AKI
seems modest. Beyond bacterial infections, AKI is also associated with severe influenza
infections in patients. In this regard, TLR7 activates B lymphocytes and contributes to
the development of glomerulonephritis in response to viral agonists [197,202]. TLR9
recognizes, among other ligands, viral and bacterial DNA motifs. Induction of TLR9
expression was reported in mouse kidney tissue after CLP [203]. Silencing of renal TLR9
with siRNA reduced cell apoptosis, attenuated the severity of AKI and increased the
survival of mice after SI-AKI induced by CLP [203]. TLR9-knockout mice have a reduced
cytokine production, splenic apoptosis, and kidney injury in SI-AKI [204]. Furthermore,
TLR9 knockout mice have lower levels of IL-17A and IL-1β after cecal ligation and puncture
producing SI-AKI [205]. Administration of chloroquine, an inhibitor of endocytic TLRs
(TLR3, TLR7, TLR8, TLR9), reduced sepsis-induced mortality and renal injury severity
in SI-AKI. In the same study, TLR9 genetic and pharmacological inhibition mirrored the
protective effect of chloroquine administration [206].
Table 3. Specific compounds targeting TLR4 on experimental AKI.
Compound AKI Model Beneficial Effects Reference
TAK-242
I/R Reduces serum creatinine and urea concentration. Decreases IL-18and malondialdehyde renal levels [190]
Rhabdomyolysis
Decreases functional and histological renal damage. Reduces renal
TNF-α, IL-6 and IL-1β levels and macrophage infiltration [161]
Decreases renal damage, serum creatinine and BUN levels. Reduces
renal IL-6, TNF-α and TLR4 expression and NFκB signaling [164]
Acetaminophen
induced AKI
Decreases histological renal damage, serum creatinine concentration
and partially restores glutathione levels [174]
Sepsis induced AKI
Improves creatinine clearance and urine output, reduces renal
neutrophil accumulation and glomerular endothelial swelling [85]
Attenuates arterial pressure, plasma creatinine and BUN levels [186]
Reduces TLR4-Myd88-NFκB signaling pathway, decreases renal
levels of TNF-α, IL-1β and IL-6 and inflammatory cell infiltration [187]
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Table 3. Cont.
Compound AKI Model Beneficial Effects Reference
Eritoran I/R Decreases serum creatinine, renal histological damage, monocyteinfiltration and inflammatory markers (TNF-α, IL-1β, CCL2) [155]
Resveratrol
I/R
Ameliorates histological renal damage, serum creatinine and BUN,
reduces renal levels of IL-6, TNF-α, IL-10, IFNγ, caspase-3 activity
and improves redox balance (MDA, SOD)
[137,138]
Rhabdomyolysis
Attenuates creatinine levels, cortical macrophage infiltration and




Improves renal function and tubular epithelial cell injury. Decreases
serum content and renal mRNA expression of TNFα, IL-1β and IL-6.
Inhibits IRE1 phosphorylation and NFκB activity in the kidney
[208]
Improves renal function, reduces serum and renal inflammation,
macrophage infiltration and TLR4 activation. Prevents endothelial





Decreases renal damage, serum creatinine and BUN. Reduces
proinflammatory TNF-α and IL-6 levels. Attenuates NFκB signaling
and increases p-JAK2 and p-STAT3 expression.
[209]
Reduces serum and renal level of TNF-α, IL-1β, IL-12, IL-18
and INF-γ [210]
Decreases renal damage and serum creatinine. Decreases
inflammatory chemokine expression, neutrophil infiltration,
intracellular ROS production and cellular apoptosis. Reduces TLR4




Decreases serum creatinine levels, endothelial damage, inflammatory
markers, redox balance and tubular cell death. Decreases TLR4 and
Myd88 gene expression and activation of NFκB and
ERK1/2 pathways
[45]
Ameliorates renal damage, inflammation and apoptosis. [212]
Cisplatin induced
AKI
Decreases serum urea and creatinine, reduces tubular necrosis,
NFκB/p65 levels and caspase-3 expression [213]
Reduces renal histological injury, and plasma creatinine and BUN
levels. Decreases renal MDA and restores renal GSH levels. Reduces
ERK1/2 phosphorylation and NFκB expression. Decreases TNFα,




Reduces proteinuria and podocyte injury. Ameliorates renal function,
decreases oxidative stress and inhibits NFκB activation. [215]
Sulforaphane Cisplatin inducedAKI
Reduces the activation of NFκB, p53, JNK and p38 pathways.





Increases survival rate, downregulates TNF-α, IL-1β and IL-6
production, inhibits the expression and activation of NFκB. [217]
NaHS
(H2S donor)
Improves renal function and kidney histopathological changes,
attenuates LPS-induced inflammation and oxidative stress,
and reduces expression of TLR4, NLRP3, and caspase-1
[78]
8.4. Thrombotic Microangiopathy-Induced AKI
One of the most common causes of AKI in children is the infection with Shiga toxin
(Stx)-producing Escherichia coli [218]. Stx causes hemolytic uremic syndrome (HUS), which
is characterized by thrombotic microangiopathy and severe renal damage [219]. TLR4
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has been identified as the specific receptor of Stx in human neutrophils [220], and its
presence increases the expression of TLR4 in renal cells [221]. Similarly, peripheral blood
monocytes from HUS patients with Stx showed higher levels of cell surface TLR4, as well as
enhanced LPS-mediated inflammatory response than control individuals [222]. However,
the soluble TLR4 extracellular domain also inhibits the interaction between Stx and human
neutrophils [223]. Therefore, the binding of TLR4 to Stx may have a protective role by
sequestering the toxin, or a harmful role by being a direct receptor of Stx, increasing its
toxicity. In a recent study, Stx increased creatinine levels in wild type and MyD88 knockout
mice, but not in TLR4 knockout mice, suggesting a crucial role of TLR4 in Stx-induced
kidney disease [224].
9. AKI to CKD Transition
AKI can actively contribute to the development of CKD, with the subsequent increase
in cardiovascular risk and death [225,226]. AKI to CKD transition is associated with
incomplete recovery of renal function over time (Figure 3). This adverse outcome is more
frequently observed in CKD patients. Other prognostic factors involved in AKI to CKD
transition include age, gender, severity, recurrence and duration of AKI, as well as classical
CKD risk factors (diabetes, hypertension, obesity and proteinuria) [15]. Although the AKI
to CKD transition is a continuum, the KDIGO-AKI workgroup has recently defined a
new concept, acute kidney disease (AKD), as the persistence of acute or subacute kidney
damage greater than 7 days, but less than 90 days, after an initial AKI event, characterizing
an intermediate pathological stage between AKI and CKD [15].Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 16 of 27 
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10. Clinical Trials Targeting TLR4 in AKI 
Many drugs targeting TLR4 are currently being evaluated in phase II and III clinical 
trials in a variety of inflammatory pathologies, such as rheumatoid arthritis, nonalcoholic 
steatohepatitis, insulin sensitivity as well as Myelodysplastic syndrome [242]. Some of 
these TLR4 inhibitors have strong anti-inflammatory effects and prevent cytokine produc-
tion in these diseases, such as Eritoran, NI-0101, CX-01 and JKB-121 [242]. This is why 
TLR4 signaling pathway has received great interest from researchers in the nephrology 
field.  
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models [243]. As previously reported, several natural (loganetin, resveratrol and curcu-
min) and synthetic compounds (TAK-242, Eritoran and hydrogen sulfide) showed bene-
ficial effects in experimental models of AKI (Table 3). Surprisingly, despite these positive 
results, at present, there is no data of clinical trials targeting TLR4 in patients suffering 
from AKI. There is only a clinical trial that analyzed the effect of the anti-inflammatory 
compound pirfenidone on renal function in septic AKI (NCT02530359). The main out-
comes include mortality, renal function, inflammation and TLR4 circulating levels. How-
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11. Perspectives and Conclusions 
TLR4 plays an important role in innate immunity via PAMPs and DAMPs recogni-
tion. However, exacerbated activation of the TLR4 signaling pathway promotes harmful 
effects in many tissues, including kidney. There is a close relationship between TLR4 and 
AKI development. A number of preclinical studies have demonstrated that TLR4 gene 
Figure 3. AKI-CKD Transition. There are multipl renal outcomes after AKI, fro full r covery of renal function to chronic
damage and permanent renal impairment. The lines on the graph represent th variation in glomerular filtration rate
(GFR) during an AKI event, according the cu ren definitions by KDIGO-AKI workgroup. The green a d blue lines show a
favorable sc nar o after an AK event, with full recovery of renal damage and no vidence of CKD. An important difference
between these lines is a better outcom in the case of an early improvement (<2 days, green line). The yellow line shows the
persistenc of acute/subacute kidney damage between the 7th and 90th day after the initial AKI event, currently called
Acute Kidney Disease (AKD). Th orange line shows an AKI event in the context of CKD. P tients suffering from AKI, i the
presence of CKD, have a higher risk of progr ssing to chroni renal damage. Th red line shows recurrent AKI eve ts in
absence of previous CKD. These mul iple injury hits significan ly reduce GFR over time. AKI episodes may be more intense
or recurrent in genetically susceptible individuals and i the presence of other risk factors, including an es ablished CKD.
Growing evidence supports that TLR4-dependent pro-inflammatory/pro-fibrotic effects ma play a key role in AKI-CKD
transition. Created with BioRend r.c m.
Int. J. Mol. Sci. 2021, 22, 816 17 of 27
Induction and maintenance of AKI-CKD transition depends on inflammatory and
fibrotic mediators expressed during initial stages of AKI [227–229]. AKI insults pro-
mote tissue damage and cell death, resulting in an early acute inflammatory response,
and subsequent reparative and regenerative reactions in late phases of AKI to restore renal
parenchyma [230,231]. However, persistent inflammatory response may conduct to the
development of fibrosis after AKI [227]. This fibrotic process is mediated by phenotypic
and functional changes of epithelial and endothelial cells toward a mesenchymal state,
the so-called epithelial to mesenchymal transition (EMT) and endothelial to mesenchymal
transition (Endo-MT). AKI-associated fibrosis is also related to the appearance of myofi-
broblasts or fibroblast-like phenotype in the kidney [232,233]. Therapeutic targets that
limit the progression of EMT and Endo-MT may play a relevant role in the progression of
AKI-associated kidney damage [234,235].
There are some studies that link TLRs with fibrosis and AKI to CKD transition [236].
TLR4 has been associated with fibroblast differentiation during AKI [237,238]. Moreover,
TLR4-deficient mice were protected against renal fibrosis due to a low expression of
α-smooth muscle actin at the tubulointerstitial level [238]. Systemic administration of
folic acid in mice has been used for studying the pathogenesis of AKI eliciting renal
fibrosis and favoring AKI-CKD transition [239]. TLR4 knockout mice protected against the
appearance of fibrosis after folic acid injection [237]. Similar results were observed after
pharmacological inhibition of the TLR4 pathway [240,241].
10. Clinical Trials Targeting TLR4 in AKI
Many drugs targeting TLR4 are currently being evaluated in phase II and III clinical
trials in a variety of inflammatory pathologies, such as rheumatoid arthritis, nonalcoholic
steatohepatitis, insulin sensitivity as well as Myelodysplastic syndrome [242]. Some of these
TLR4 inhibitors have strong anti-inflammatory effects and prevent cytokine production
in these diseases, such as Eritoran, NI-0101, CX-01 and JKB-121 [242]. This is why TLR4
signaling pathway has received great interest from researchers in the nephrology field.
The effects of specific TLR4 inhibitors have been analyzed in many preclinical AKI
models [243]. As previously reported, several natural (loganetin, resveratrol and curcumin)
and synthetic compounds (TAK-242, Eritoran and hydrogen sulfide) showed beneficial
effects in experimental models of AKI (Table 3). Surprisingly, despite these positive results,
at present, there is no data of clinical trials targeting TLR4 in patients suffering from AKI.
There is only a clinical trial that analyzed the effect of the anti-inflammatory compound
pirfenidone on renal function in septic AKI (NCT02530359). The main outcomes include
mortality, renal function, inflammation and TLR4 circulating levels. However, results are
currently pending.
11. Perspectives and Conclusions
TLR4 plays an important role in innate immunity via PAMPs and DAMPs recogni-
tion. However, exacerbated activation of the TLR4 signaling pathway promotes harmful
effects in many tissues, including kidney. There is a close relationship between TLR4 and
AKI development. A number of preclinical studies have demonstrated that TLR4 gene
deficiency or inhibition ameliorated renal function, decreased histological damage and
reduced inflammation, oxidative stress and cell death in different types of AKI. Moreover,
TLR4 is also related to AKI to CKD transition by promoting fibrosis. However, to our
knowledge, no clinical trials have been designed to specifically analyze whether TLR4
targeting is beneficial for patients with AKI. Further studies in humans are necessary to
validate the potential favorable effect of TLR4 inhibition against AKI.
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